Phase II study of first line capecitabine administered on continuous way combined with oxaliplatin and bevacizumab every two weeks in metastatic colorectal cancer patients.

Trial Profile

Phase II study of first line capecitabine administered on continuous way combined with oxaliplatin and bevacizumab every two weeks in metastatic colorectal cancer patients.

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2011

At a glance

  • Drugs Bevacizumab; Capecitabine; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Aug 2011 Planned end date changed from 1 Jun 2009 to 1 Jan 2011 as reported by ClinicalTrials.gov.
    • 02 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top